Drug Trial Radar · NCT06099184
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
Last checked: Nov 20, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jan 15, 2024
Primary completion
Oct 24, 2024
Study completion Oct 24, 2024
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Conditions
- Diabetic Macular Edema
Interventions
EYP-1901Drug
Intravitreal Injection
Aflibercept 2Mg/0.05Ml Inj,OphDrug
Intravitreal Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs AfliberceptTime frame: Week 24
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
EyePoint Investigative Site
Phoenix, Arizona
EyePoint Investigative Site
Lemont, Illinois
EyePoint Investigative Site
Hagerstown, Maryland
EyePoint Investigative Site
Reno, Nevada
EyePoint Investigative Site
Erie, Pennsylvania
EyePoint Investigative Site
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.